#1 Clinical Trials Search in Europe

Cefaclor

Cefaclor is a second-generation cephalosporin antibiotic used to treat various bacterial infections. This article examines recent clinical trials that have studied the use of cefaclor in different medical conditions. From preventing infections in children with biliary atresia to treating serious heart infections and evaluating potential allergic reactions, these trials provide valuable insights into how cefaclor is being used in modern medicine. Understanding these applications can help patients and healthcare providers make informed decisions about treatment options involving this antibiotic.

Table of Contents

What is Cefaclor?

Cefaclor is a second-generation cephalosporin antibiotic medication. Cephalosporins belong to a larger class of antibiotics called beta-lactams, which also includes penicillins. Cefaclor is used to treat various bacterial infections by stopping the growth of bacteria[1].

Cefaclor is available in different formulations, including oral capsules and suspension for oral administration. It’s also sometimes used in clinical trials in combination with other antibiotics to treat or prevent specific bacterial infections[2].

How Cefaclor Works

As a cephalosporin antibiotic, cefaclor works by interfering with the bacteria’s cell wall synthesis. Specifically, it binds to proteins called penicillin-binding proteins (PBPs) that are essential for bacterial cell wall formation. By disrupting this process, cefaclor weakens the bacterial cell wall, causing the bacteria to rupture and die[3].

Cefaclor is effective against many types of bacteria, including both gram-positive and some gram-negative bacteria. This makes it useful for treating various types of infections throughout the body[1].

Medical Conditions Treated with Cefaclor

Based on clinical trial information, cefaclor is used to treat or prevent several types of bacterial infections[1][2]:

  • Respiratory infections – Including bronchitis, pneumonia, and other respiratory tract infections
  • Ear infections – Including otitis media (middle ear infection)
  • Urinary tract infections – Caused by susceptible bacteria
  • Skin infections – Various skin and soft tissue infections
  • Prevention of cholangitis – Used prophylactically (preventively) in patients with biliary atresia after Kasai portoenterostomy surgery[3]

In the clinical trial focused on biliary atresia, cefaclor was used as part of a prophylactic (preventive) oral antibiotic regimen. This treatment was aimed at preventing cholangitis, which is an inflammation of the bile ducts often caused by bacterial infection. Cholangitis is a common complication after Kasai portoenterostomy (KP), a surgical procedure used to treat biliary atresia in infants[3].

Dosage Information

Based on the clinical trials reviewed, cefaclor dosing can vary depending on the condition being treated, patient age, and other factors. Some examples include:

  • For prophylactic use in preventing cholangitis after Kasai portoenterostomy: 12.5 mg/kg/day taken orally, alternated every 2 weeks with another antibiotic (sulfamethoxazole/trimethoprim)[3]
  • For standard adult dosing in capsule form: 2 grams per day[2]

It’s important to note that these dosages are from specific clinical trials and may not represent the full range of approved dosages. Always follow your healthcare provider’s instructions for taking cefaclor, including the dosage and duration of treatment[1].

Administration Methods

Cefaclor is available in different forms for different administration methods[1][2]:

  • Oral capsules – Swallowed whole with water, typically with or without food
  • Oral suspension – Liquid form that needs to be shaken well before measuring the dose

In the clinical trials reviewed, cefaclor was primarily administered orally. For example, in the study on preventing cholangitis after Kasai portoenterostomy, cefaclor was given orally at a dose of 12.5 mg/kg/day, alternating every 2 weeks with another antibiotic[3].

Use in Clinical Studies

Cefaclor has been studied in various clinical trials, including:

1. Prevention of Cholangitis After Kasai Portoenterostomy in Biliary Atresia

In a non-inferiority trial, cefaclor was used as part of a prophylactic oral antibiotic regimen to prevent cholangitis in patients with biliary atresia after Kasai portoenterostomy surgery. In this study, cefaclor (12.5 mg/kg/day) was alternated every 2 weeks with compound sulfamethoxazole (25 mg/kg/day) from post-operation day 15 to month 6[3].

The study aimed to investigate whether prophylactic oral antibiotics could effectively prevent cholangitis, which is a common complication after this surgery. Cholangitis can occur when intestinal bacteria ascend into the intrahepatic biliary system or through bacterial colonization[3].

2. Cephalosporin Allergy Testing

Cefaclor was included in a clinical trial designed to optimize the diagnostic approach to cephalosporin allergy testing. In this study, cefaclor was one of several cephalosporin antibiotics being evaluated through skin testing and controlled drug challenges to better understand cephalosporin allergies and cross-reactivity with other beta-lactam antibiotics[1].

The study explored the mechanism of cephalosporin allergies and aimed to determine the optimal approach for evaluating patients with suspected cephalosporin allergies[1].

3. Oral Antimicrobial Treatment for Infective Endocarditis

Cefaclor was also included in a clinical trial comparing oral antimicrobial treatment versus outpatient parenteral therapy for infective endocarditis. In this study, cefaclor capsules (2 grams per day) were included as one of the potential oral antibiotics that could be used in the treatment of infective endocarditis[2].

This non-inferiority trial aimed to investigate whether oral antibiotic therapy could be as effective as parenteral (intravenous) therapy for treating infective endocarditis, potentially improving patient quality of life and reducing treatment costs[2].

Potential Side Effects and Allergic Reactions

Like all medications, cefaclor can cause side effects. Based on the clinical trials reviewed, potential side effects and allergic reactions include[1]:

  • Allergic reactions – Ranging from mild skin rashes to severe anaphylaxis
  • Gastrointestinal issues – Such as nausea, vomiting, diarrhea
  • Superinfections – Overgrowth of non-susceptible organisms due to antibiotic use

Cephalosporin allergies, including allergies to cefaclor, are an important consideration in antibiotic treatment. One of the clinical trials specifically focused on optimizing the diagnostic approach to cephalosporin allergy testing, indicating that allergic reactions to cefaclor and other cephalosporins are a significant clinical concern[1].

If you experience symptoms such as rash, itching, swelling (especially of the face, tongue, or throat), severe dizziness, or trouble breathing after taking cefaclor, seek immediate medical attention as these could be signs of a serious allergic reaction[1].

Precautions and Considerations

Based on the clinical trials reviewed, there are several important precautions and considerations to keep in mind when using cefaclor[1][2][3]:

  • Allergy history – If you have a history of allergic reactions to cephalosporins, penicillins, or other beta-lactam antibiotics, inform your healthcare provider before taking cefaclor
  • Cross-reactivity – There may be cross-reactivity between different cephalosporins and between cephalosporins and penicillins, meaning that if you’re allergic to one, you might also be allergic to others
  • Long-term use – Long-term use of antibiotics, including cefaclor, may lead to antibiotic resistance, intestinal flora disturbance, and increase the risk of allergies and autoimmune diseases
  • Liver function – In patients with liver dysfunction, antibiotics should be used cautiously as they may increase the burden on the liver

One of the clinical trials noted that there is controversy about the use of prophylactic antibiotics, including cefaclor, after Kasai portoenterostomy for biliary atresia. While antibiotics may help prevent cholangitis, long-term use could have potential drawbacks that need to be considered[3].

Always follow your healthcare provider’s instructions when taking cefaclor or any antibiotic. Complete the full course of treatment, even if you start feeling better before it’s finished, to ensure the infection is fully treated and to reduce the risk of antibiotic resistance[2].

Trial Identifier Condition Use of Cefaclor Dosage Administration Key Outcomes Measured
NCT05925309 Biliary Atresia (post Kasai portoenterostomy) Prophylactic antibiotic to prevent cholangitis 12.5 mg/kg/day Oral, alternated every 2 weeks with sulfamethoxazole Occurrence of cholangitis, jaundice clearance, liver parameters, changes in intestinal flora
NCT06406114 Cephalosporin Allergy Testing Used in skin testing and drug challenges to assess allergic reactions Various concentrations for testing Skin tests and oral challenges Allergic reactions, cross-reactivity with similar and dissimilar cephalosporins
NCT05398679 Infective Endocarditis Treatment option for infective endocarditis 2 grams/day Both oral (capsules) and intravenous formulations Unplanned hospitalizations, mortality, relapses, quality of life, treatment costs

FAQ

  • What is cefaclor and how does it work? Cefaclor is a second-generation cephalosporin antibiotic that works by preventing bacteria from building their cell walls, which ultimately kills the bacteria. It belongs to the beta-lactam family of antibiotics and is effective against many common bacterial infections. In the clinical trials discussed, cefaclor was used at various dosages depending on the condition being treated, including 12.5 mg/kg/day for children with biliary atresia and 2 grams per day for adults with infective endocarditis.
  • In which medical conditions is cefaclor being studied? Based on the clinical trials data, cefaclor is being studied in several conditions: 1) As a prophylactic (preventive) oral antibiotic to prevent cholangitis (bile duct infection) in children after Kasai portoenterostomy surgery for biliary atresia; 2) As part of a treatment regimen for infective endocarditis (heart valve infection) in both oral and parenteral (injectable) forms; and 3) In studies examining cephalosporin allergies and cross-reactivity between different types of antibiotics.
  • How is cefaclor being used in children with biliary atresia? In children with biliary atresia who have undergone Kasai portoenterostomy surgery, cefaclor is being used as a prophylactic (preventive) oral antibiotic. In the trial, it was administered at a dose of 12.5 mg/kg/day and alternated every two weeks with compound sulfamethoxazole tablets. This preventive antibiotic treatment begins about 15 days after surgery and continues for up to 6 months. The study aims to determine if this approach helps prevent cholangitis, a common and serious complication after this surgery.
  • What are the potential side effects or risks of cefaclor treatment? While the clinical trials don't specifically list all side effects of cefaclor, they do mention some general concerns with long-term antibiotic use including: increased burden on liver function (especially important in conditions like biliary atresia), potential development of antibiotic resistance, disturbance of intestinal flora (gut bacteria), and increased risk of allergies and autoimmune diseases. One trial specifically studies allergic reactions to cephalosporins including cefaclor, which can range from mild skin reactions to severe anaphylaxis (a serious, life-threatening allergic reaction).
  • Can people with cephalosporin allergies take cefaclor? People with known or suspected cephalosporin allergies should not take cefaclor without proper evaluation. One of the clinical trials is specifically studying cephalosporin allergies, including cefaclor, to determine cross-reactivity patterns between different cephalosporins and other beta-lactam antibiotics. The study includes skin testing and controlled drug challenges to better understand which patients with allergies to one cephalosporin might safely take another. If you have a history of antibiotic allergies, it's important to discuss this with your healthcare provider before taking cefaclor.

Ongoing Clinical Trials on Cefaclor

  • Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Biliary Atresia: A rare disease in newborns where the bile ducts inside or outside the liver are abnormally narrow, blocked, or absent. This condition prevents bile from flowing from the liver to the intestines, causing liver damage and potentially leading to liver failure if untreated.
  • Kasai Portoenterostomy (KP): A surgical procedure performed on infants with biliary atresia to restore bile flow from the liver to the intestine. During this operation, the surgeon removes the blocked bile ducts and connects the small intestine directly to the liver.
  • Cholangitis: An infection or inflammation of the bile ducts, which carry bile from the liver to the gallbladder and small intestine. In the context of biliary atresia, it's a common complication after Kasai portoenterostomy, with symptoms including fever, jaundice, and abdominal discomfort.
  • Cephalosporin: A class of antibiotics that includes cefaclor. Cephalosporins are grouped into generations (first, second, third, etc.) based on when they were developed and their spectrum of activity against bacteria. Cefaclor is a second-generation cephalosporin.
  • Prophylactic Antibiotics: Antibiotics given to prevent rather than treat an infection. In the biliary atresia trial, cefaclor was used prophylactically to prevent cholangitis after surgery.
  • Beta-lactam Antibiotics: A class of antibiotics that includes penicillins, cephalosporins (like cefaclor), monobactams, and carbapenems. They share a common structure called a beta-lactam ring and work by interfering with bacterial cell wall synthesis.
  • Infective Endocarditis: An infection of the inner lining of the heart chambers and valves (endocardium), usually caused by bacteria. It can damage heart valves and is potentially life-threatening if not treated properly.
  • Anaphylaxis: A severe, potentially life-threatening allergic reaction that can occur rapidly after exposure to an allergen, including certain antibiotics like cefaclor. Symptoms can include difficulty breathing, swelling of the throat or tongue, drop in blood pressure, and loss of consciousness.
  • Cross-reactivity: When an allergic reaction to one substance also occurs with a similar but different substance. In antibiotic allergies, cross-reactivity refers to when a patient allergic to one antibiotic (like a specific cephalosporin) also reacts to another related antibiotic.
  • Drug Challenge: A procedure where a medication is given to a patient in gradually increasing doses under medical supervision to determine if they will have an allergic reaction. This is used in the cephalosporin allergy trial to confirm true allergies.
  • Skin Testing: A diagnostic procedure to identify allergies where small amounts of potential allergens are applied to the skin (either as a scratch or an injection) to observe if an allergic reaction occurs. This is used in the cephalosporin allergy trial.
  • OPAT (Outpatient Parenteral Antibiotic Therapy): Administration of intravenous antibiotics to patients outside of a hospital setting, allowing them to receive necessary treatment at home or in an outpatient facility.
  • Nocebo Response: A negative physical reaction experienced by a patient that is attributed to a treatment but is actually caused by the patient's negative expectations rather than the treatment itself. This is being studied in the cephalosporin allergy trial.
  • Jaundice Clearance: The resolution of jaundice (yellowing of the skin and eyes due to high bilirubin levels). In the biliary atresia trial, this is defined as total bilirubin less than 20 μmol/L.

References

  1. https://clinicaltrials.gov/study/NCT06406114
  2. https://clinicaltrials.gov/study/NCT05398679
  3. https://clinicaltrials.gov/study/NCT05925309